{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-23-023068","form_type":"8-K","ticker":"ERNA","cik":"0000748592","company_name":"Ernexa Therapeutics Inc.","filed_at":"2023-05-05T23:59:59+00:00","discovered_at":"2026-05-14T18:03:42.147625+00:00","generated_at":"2026-06-15T18:39:42.291107+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Eterna Therapeutics appoints Sandra Gurrola as PFO; CFO Jackson resigns with $207,500 severance","bullets":["Andrew Jackson resigned as CFO effective May 4, 2023; receives $207,500 salary continuation for 6 months plus COBRA premiums.","Sandra Gurrola appointed as principal financial officer effective May 5, 2023; she was previously VP Finance.","Jackson forfeited 33,239 unvested stock options granted June 3, 2022.","Separation agreement includes general release, cooperation, and confidentiality provisions."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-23-023068","json":"https://secwatch.observer/filing/0001140361-23-023068.json","markdown":"https://secwatch.observer/filing/0001140361-23-023068.md","text":"https://secwatch.observer/filing/0001140361-23-023068.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/748592/000114036123023068/0001140361-23-023068-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/748592/000114036123023068/brhc20052521_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T18:39:42.291107+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"733228a2ca","claim":"Andrew Jackson resigned as Chief Financial Officer at Ernexa Therapeutics Inc..","evidence_excerpt":"Mr. Jackson resigned from his position as Chief Financial Officer (principal financial officer) and as an officer, director, manager or employee of the Company’s subsidiaries.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/748592/000114036123023068/0001140361-23-023068-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Chief Financial Officer"}],"fact_type":"executive_change"},{"claim_id":"d0b316ba5c","claim":"Sandra Gurrola was appointed as principal financial officer at Ernexa Therapeutics Inc..","evidence_excerpt":"appointed Sandra Gurrola, the Company’s current Vice President, Finance (and principal accounting officer), as the Company’s principal financial officer, which appointment became effective on May 5, 2023.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/748592/000114036123023068/0001140361-23-023068-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"principal financial officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}